Update
$Adverum Biotechnologies(ADVM.US$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk profile at both dose levels –
– Ozurdex + difluprednate identified as potential "go-forward" prophylaxis –
– The vast majority of patients on the "go-forward" regimen had no inflammation and >90% of patients have no or minimal inflammation (0 or 0.5+ AC cells) –
– Preliminary efficacy and safety data trending similar to or better than the OPTIC study, in which patients continue to see on-going clinical benefit through at least 3 years –![]()
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk profile at both dose levels –
– Ozurdex + difluprednate identified as potential "go-forward" prophylaxis –
– The vast majority of patients on the "go-forward" regimen had no inflammation and >90% of patients have no or minimal inflammation (0 or 0.5+ AC cells) –
– Preliminary efficacy and safety data trending similar to or better than the OPTIC study, in which patients continue to see on-going clinical benefit through at least 3 years –
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
QianmengYu : nice!
QianmengYu : drop to halt. Hmmm